PR 104

Drug Profile

PR 104

Alternative Names: PR-104; SN-29244

Latest Information Update: 22 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Proacta Therapeutics
  • Developer Proacta; Proacta Therapeutics
  • Class Antineoplastics; Benzamides; Nitrogen mustard compounds; Small molecules
  • Mechanism of Action Alkylating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Acute myeloid leukaemia; Solid tumours
  • Discontinued Hepatocellular carcinoma; Non-small cell lung cancer; Small cell lung cancer

Most Recent Events

  • 22 Sep 2015 No recent reports on development identified - Phase-I for Solid tumours in New Zealand (IV)
  • 22 Sep 2015 No recent reports on development identified - Phase-I/II for Acute myeloid leukaemia in USA (IV)
  • 15 Nov 2011 Adverse events data from a phase I trial in Solid tumours presented at the 23rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2011)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top